Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.   Report issue

For profit Phase 3
Founded: Jiangsu China (2012)

Organization Overview

First Clinical Trial
2018
NCT03906006
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (2)

abp-671 (5 trials)

allopurinol (zyloprim) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Gout (Phase 2)

Hyperuricemia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 2